Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Lenoir Memorial Cancer Center
mi
from
Kinston, NC
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Lenoir Memorial Cancer Center
mi
from
Kinston, NC
Click here to add this to my saved trials
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Comprehensive Cancer Center at Moore Regional Hospital
mi
from
Pinehurst, NC
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Comprehensive Cancer Center at Moore Regional Hospital
mi
from
Pinehurst, NC
Click here to add this to my saved trials
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Zimmer Cancer Center at New Hanover Regional Medical Center
mi
from
Wilmington, NC
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Zimmer Cancer Center at New Hanover Regional Medical Center
mi
from
Wilmington, NC
Click here to add this to my saved trials
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
mi
from
Columbus, OH
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Oklahoma University Medical Center
mi
from
Oklahoma City, OK
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Oklahoma University Medical Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
The Miriam Hospital (Lifespan)
mi
from
Providence, RI
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
The Miriam Hospital (Lifespan)
mi
from
Providence, RI
Click here to add this to my saved trials
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Veterans Affairs Medical Center - Dallas
mi
from
Dallas, TX
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Veterans Affairs Medical Center - Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Vermont Cancer Center at University of Vermont
mi
from
Burlington, VT
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Vermont Cancer Center at University of Vermont
mi
from
Burlington, VT
Click here to add this to my saved trials
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Cancer Care Center at Martha Jefferson Hospital
mi
from
Charlottesville, VA
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Cancer Care Center at Martha Jefferson Hospital
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Virginia Oncology Associates - Norfolk
mi
from
Norfolk, VA
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Virginia Oncology Associates - Norfolk
mi
from
Norfolk, VA
Click here to add this to my saved trials
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
MBCCOP - Massey Cancer Center
mi
from
Richmond, VA
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
MBCCOP - Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Oncology and Hematology Associates of Southwest Virginia, Incorporated - Roanoke
mi
from
Roanoke, VA
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Oncology and Hematology Associates of Southwest Virginia, Incorporated - Roanoke
mi
from
Roanoke, VA
Click here to add this to my saved trials
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
St Mary's Medical Center
mi
from
Huntington, WV
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
St Mary's Medical Center
mi
from
Huntington, WV
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
CCOP - Wichita
mi
from
Wichita, KA
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
Medcenter One Health System
mi
from
Bismarck, ND
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
Medcenter One Health System
mi
from
Bismarck, ND
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
Altru Health Systems
mi
from
Grand Forks, ND
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
Altru Health Systems
mi
from
Grand Forks, ND
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
CCOP - Toledo Community Hospital Oncology Program
mi
from
Toledo, OH
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
CCOP - Toledo Community Hospital Oncology Program
mi
from
Toledo, OH
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Providence Saint Joseph Medical Center - Burbank
mi
from
Burbank, CA
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Providence Saint Joseph Medical Center - Burbank
mi
from
Burbank, CA
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Moores UCSD Cancer Center
mi
from
La Jolla, CA
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Moores UCSD Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Kaiser Permanente Medical Office -Vandever Medical Office
mi
from
San Diego, CA
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Kaiser Permanente Medical Office -Vandever Medical Office
mi
from
San Diego, CA
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Beebe Medical Center
mi
from
Lewes, DE
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Beebe Medical Center
mi
from
Lewes, DE
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Rush-Copley Cancer Care Center
mi
from
Aurora, IL
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Rush-Copley Cancer Care Center
mi
from
Aurora, IL
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
University of Illinois Cancer Center
mi
from
Chicago, IL
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
University of Illinois Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Joliet Oncology-Hematology Associates, Limited - West
mi
from
Joliet, IL
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Joliet Oncology-Hematology Associates, Limited - West
mi
from
Joliet, IL
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Carle Cancer Center at Carle Foundation Hospital
mi
from
Urbana, IL
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Carle Cancer Center at Carle Foundation Hospital
mi
from
Urbana, IL
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
St. Francis Hospital and Health Centers - Beech Grove Campus
mi
from
Beech Grove, IN
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
St. Francis Hospital and Health Centers - Beech Grove Campus
mi
from
Beech Grove, IN
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Saint Anthony Memorial Health Centers
mi
from
Michigan City, IN
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Saint Anthony Memorial Health Centers
mi
from
Michigan City, IN
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Reid Hospital & Health Care Services, Incorporated
mi
from
Richmond, IN
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Reid Hospital & Health Care Services, Incorporated
mi
from
Richmond, IN
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Tammy Walker Cancer Center at Salina Regional Health Center
mi
from
Salina, KA
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Tammy Walker Cancer Center at Salina Regional Health Center
mi
from
Salina, KA
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Cotton-O'Neil Cancer Center
mi
from
Topeka, KA
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Cotton-O'Neil Cancer Center
mi
from
Topeka, KA
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
St. Francis Comprehensive Cancer Center
mi
from
Topeka, KA
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
St. Francis Comprehensive Cancer Center
mi
from
Topeka, KA
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Central Maine Comprehensive Cancer Center at Central Maine Medical Center
mi
from
Lewiston, ME
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Central Maine Comprehensive Cancer Center at Central Maine Medical Center
mi
from
Lewiston, ME
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Union Hospital Cancer Program at Union Hospital
mi
from
Elkton MD, MD
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Union Hospital Cancer Program at Union Hospital
mi
from
Elkton MD, MD
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Dana-Farber/Brigham and Women's Cancer Center
mi
from
Boston, MA
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Dana-Farber/Brigham and Women's Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Cancer Research Center at Boston Medical Center
mi
from
Boston, MA
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Cancer Research Center at Boston Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/14/2015
Borgess Medical Center
mi
from
Kalamazooaa, MI
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/14/2015
Borgess Medical Center
mi
from
Kalamazooaa, MI
Click here to add this to my saved trials